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The interferon-induced transmembrane (IFITM) pro-
teins protect cells from diverse virus infections by
inhibiting virus-cell fusion. IFITM proteins also inhibit
HIV-1 replication through mechanisms only partially
understood. We show that when expressed in unin-
fected lymphocytes, IFITM proteins exert protective
effects during cell-free virus infection, but this re-
striction can be overcome upon HIV-1 cell-to-cell
spread. However, when present in virus-producing
lymphocytes, IFITM proteins colocalize with viral
Env and Gag proteins and incorporate into nascent
HIV-1 virions to limit entry into new target cells. IFITM
in viral membranes is associated with impaired virion
fusion, offering additional and more potent defense
against virus spread. Thus, IFITM proteins act addi-
tively in both productively infected cells and unin-
fected target cells to inhibit HIV-1 spread, potentially
conferring these proteins with greater breadth and
potency against enveloped viruses.
INTRODUCTION
Viruses, as obligate intracellular parasites, seize control of
various compartments of the host cell to complete their life cycle.
Viral replication requires the recruitment of cellular cofactors as
well as the evasion of cell-intrinsic immune effectors that protect
nearly every cellular niche from viral invasion. These antiviral fac-
tors, known as host restriction factors, reside in the cytoplasm,
the nucleus, the plasma membrane, and the viral particle itself.
The localization of restriction factors in the cell often corre-
sponds to the step of the virus life cycle with which it interferes.
For example, the nuclear dNTPase SAMHD1depletes the pool of
nucleotide triphosphates needed for viral reverse transcription
(Laguette and Benkirane, 2012), while Mx2 restricts a postentry
event in the cytoplasm prior to integration (Haller, 2013). APO-
BEC3G becomes incorporated into nascent budding virions
and hypermutates the viral genome (Malim and Bieniasz,736 Cell Host & Microbe 16, 736–747, December 10, 2014 ª2014 Els2012). Tetherin (or BST-2) traps virions to the plasmamembrane,
blocking their release (Malim and Bieniasz, 2012). Newcomers to
this category of membrane-bound restriction factors are the
interferon-induced transmembrane (IFITM) proteins.
The human genome encodes at least five IFITM proteins,
including three members with reported antiviral activity (IFITM1,
IFITM2, and IFITM3) (Brass et al., 2009; Diamond and Farzan,
2013; Perreira et al., 2013; Smith et al., 2014). The antiviral IFITM
proteins are nearly ubiquitously expressed and are further upre-
gulated by type I interferons (IFN) (Siegrist et al., 2011). IFITM5
expression is restricted to osteoblasts and is required for bone
mineralization, while the function of IFITM10 is unknown
(Diamond and Farzan, 2013). Residents of cellular membranes
at the interior and exterior of the cell, IFITM1, IFITM2, and IFITM3
may represent the earliest acting restriction factors yet identified.
Previous reports demonstrate that they block virus entry (Brass
et al., 2009; Huang et al., 2011) at the level of virus-cell fusion
by affecting the biophysical properties (Desai et al., 2014; Li
et al., 2013) or composition (Amini-Bavil-Olyaee et al., 2013) of
the cellular membranes in which they are found. These proteins
display antiviral function against many enveloped viruses,
including influenza A virus (IAV), West Nile virus, dengue virus,
severe acute respiratory syndrome coronavirus, hepatitis C
virus, and Ebola virus (Perreira et al., 2013). While the majority
of studies have relied on in vitro infection systems, it is well
established that IFITM3 restricts IAV infection in vivo. Ifitm3-defi-
cient mice fail to clear infection by otherwise mild strains of IAV
(Bailey et al., 2012; Everitt et al., 2012), while a polymorphism
in human ifitm3 is enriched in patients hospitalized for severe
influenza disease (Everitt et al., 2012). IFITM proteins have also
been reported to inhibit HIV-1 replication. IFITM2 and IFITM3
impact HIV-1 entry, while IFITM1 may act by additional mecha-
nisms (Jia et al., 2012; Lu et al., 2011). However, the effect on
HIV-1 entry is relatively modest and depends on the experi-
mental system (Brass et al., 2009; Lu et al., 2011). Establishing
IFITM proteins as bona fide restriction factors of HIV-1, or any
virus, will require the use of relevant in vitro assays, as well as
an understanding of if and how the virus evades or antagonizes
this activity. Furthermore, since IFITM proteins also play roles
in cell adhesion, antiproliferation, and signaling (Diamond and
Farzan, 2013), it is important to identify additional functions
that these proteins may perform during viral infection.evier Inc.
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Figure 1. IFITM3 in Virus-Producing Cells Restricts HIV-1 Cell-to-
Cell Transmission
(A) SupT1 cells were treatedwith doxycycline to induce FLAG-IFITM3 (see also
Figure S1) before infection with NL4-3 HIV-1. Viral replication was followed by
intracellular Gag staining at the days indicated. Left: one representative
experiment. Right: mean ± SD of three independent experiments at day 3 p.i.,
with viral inoculum varying from 1 to 12 ng/ml p24.
(B) SupT1 cells were infected with NL4-3. When 30%–50% of the cells were
Gag+, IFITM3 was induced, or not induced, overnight with doxycycline. These
donor cells were cocultivated 2 hr with labeled SupT1 target cells expressing
or not expressing IFITM3. Target cells were sorted, and transmission was
monitored by the fraction of Gag+ target cells at the days indicated. Left: one
representative experiment. Right: mean ± SD of three independent experi-
ments at day 2 p.i., with increasing amounts of infection among donor cells,
varying from 30% to 50%.
(C) Schematic illustration of the four combinations of cells tested.
(D) One representative experiment. Cocultures were performed as described
in (B).
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IFITM Proteins in HIV Membranes Restrict Fusion
Cell Host &Using an in vitro coculture system designed to measure virus
spread between lymphocytes, we report anti-HIV functions of
IFITM proteins in virus-producing cells. IFITM proteins present
in the uninfected cell are poorly effective at blocking HIV-1 entry,
yet in cells that are already infected, they incorporate into virions
and diminish virus infectivity. We demonstrate that IFITM
proteins exert their anti-HIV activity most potently from within
the virus membrane. Thus, this class of restriction factor
impinges on the viral life cycle of HIV-1, and possibly other envel-
oped viruses, at multiple steps.
RESULTS
Revealing the Antiviral Potential of IFITM Proteins
in Virus-Producing Cells
While the role of IFITM proteins as inhibitors of virus entry is well
established, the experimental systems used to characterize this
antiviral function have relied on cell-free virus infections (Smith
et al., 2014). However, HIV-1 spreads effectively in culture and
likely within infected individuals by passing directly between
cells in a process known as cell-to-cell transmission (Dale
et al., 2013; Sattentau, 2011; Sourisseau et al., 2007; Murooka
et al., 2012). We used previously described doxycycline-
inducible CD4+ SupT1 T cell lines (Figure S1A, available online),
engineered to allow expression of FLAG-IFITM3, to describe
their effect during HIV-1 replication. In these cells, a fraction of
IFITM3 is found at the cell surface, as assessed by flow cytom-
etry (Figure S1B).
As reported (Lu et al., 2011), induction of IFITM3 in target cells
followed by incubation with cell-free virions resulted in a potent
block to viral replication (Figure 1A). However, increasing the
viral inoculum lead to a lessmarked restriction (Figure S1C), sug-
gesting that this antiviral effect may be partly saturable. We then
assessed the ability of IFITM to impact direct viral cell-to-cell
spread. We used a transient coculture system (Malbec et al.,
2013; Sourisseau et al., 2007), in which HIV-1-infected donor
T cells were mixed with dye-labeled SupT1 target cells. After
2 hr of coculture, target cells were isolated using a cell sorter.
Infection of target cells was assessed up to 3 days later by
measuring Gag expression (Figure 1B). The Gag signal in targets
was due to de novo synthesis, since it was significantly reduced
in the presence of reverse transcriptase inhibitor Nevirapine
(data not shown). In contrast to cell-free HIV-1, when infections
were performed by coculture, the induction of IFITM3 in target
cells had little to no effect on inhibiting virus spread (Figure 1B).
This lack of antiviral effect was observed when donor cells
were infected at different levels (Figure 1B). Thus, IFITM3-ex-
pressing cells are no longer protected against infection from(E) Mean ± SD of three independent experiments at day 2 p.i.
(F) 293T cells were transfected with pNL4-3 and FLAG-IFITM3 expression
plasmids and cocultivated with SupT1 target cells expressing or not ex-
pressing IFITM3 for 2 hr. Target cells were harvested, and transmission was
monitored by measuring the fraction of Gag+ target cells. Mean ± SD of four
independent experiments at day 2 p.i. Levels of Gag in the target cells in the
absence of IFITM3 in both donors and targets were normalized to 100%. A
one-sample t test was performed in (E) and (F), *p < 0.05. Comparisons were
made between the condition indicated and the IFITM3/ condition. See also
Figure S1.
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IFITM Proteins in HIV Membranes Restrict Fusioncell-associated virus, partly because local titers using virus-pro-
ducing cells are high. This led us to ask whether IFITM3 pos-
sesses other antiviral functions that are robust to this mode of
HIV spread. We modified the coculture system to include condi-
tions in which IFITM3 was induced either in infected donors,
in targets, or in both (Figure 1C). While IFITM3 in uninfected
target cells had minimal effect, IFITM3 in the donors decreased
HIV transmission approximately 2-fold (Figures 1D and 1E).
A more potent inhibition was observed when both donors and
targets expressed IFITM3, which resulted in a 5-fold decrease
in productive target cell infection. This unexpected role of
IFITM3 was confirmed using another coculture system in which
the virus does not spread in the donor cells. We cotransfected
293T cells with an HIV-1 provirus and an IFITM3-expressing
plasmid and cocultured them with IFITM3-negative or -positive
SupT1 cells. A 5-fold inhibition of virus transmission to target
cells was observed in this system, and inhibition was further
enhanced when target cells also expressed IFITM3 (Figure 1F).
Titration of the ifitm3-encoding plasmid demonstrated that
inhibition of transmission was dependent on the amount of
IFITM3, while a control plasmid encoding MxA had no effect
(Figure S1D).
Together, these coculture experiments identify that HIV-1, by
spreading intercellularly, escapes canonical IFITM-mediated
restriction in the uninfected target cell. However, IFITM proteins
potently inhibit the spread of virus from cells that are already
infected.
Real-Time Analysis of the Impact of IFITM3 on HIV-1
Cell-to-Cell Spread
To further document the effect of IFITM3, we performed a
dynamic analysis of viral spread, using HIV-1 encoding an
IRES GFP cassette (Wildum et al., 2006). Infected SupT1 cells
were mixed with target SupT1 cells expressing an RFP marker.
Cells were then plated in microdishes coated with fibronectin
and visualized by time-lapse fluorescence microscopy with
images acquired every 5 min for up to 60 hr. Representative ex-
amples of viral spread, in the absence of IFITM3 or with IFITM3
expressed in both donors and targets, are shown in Movie S1.
Time-lapse analysis showed that in the absence of IFITM3,
HIV-1 efficiently spread to new targets, measured as double
GFP+ RFP+ objects (Figures 2A and S2A). IFITM3 significantly
impaired viral propagation, with a 4-fold decrease in the number
of newly infected target cells after 60 hr of continuous coculture
(Figure 2A). As expected, an Env-defective virus (HIV-1DEnv) did
not spread to new recipients (Figure 2A), and Nevirapine abro-
gated viral replication (data not shown). Cells were interrogated
at the end of the coculture by flow cytometry to confirm the effect
of IFITM3 on viral spread (Figure S2B). We then visually scored
the appearance of syncytia, identified as giant GFP+RFP+
cells eventually displaying bubble-like membrane extensions
(Figure 2C). IFITM3 strongly decreased the number of syncytia
observed, a phenomenon previously attributed to IFITM proteins
in the context of other viruses (Li et al., 2013; Lin et al., 2013) (Fig-
ures 2B and 2C). Image extraction at different time points
demonstrated that in the presence of IFITM3, infected donor
GFP+ cells formed clusters with target RFP+ cells, but in most
cases these structures did not lead to cell fusion (Figures 2B
and 2C). We also performed a time-lapse microscopy analysis738 Cell Host & Microbe 16, 736–747, December 10, 2014 ª2014 Elsof viral spread when IFITM3 was induced in donors or in targets
alone. The main antiviral effect was observed when IFITM3 was
present in the donor cells (Figure S2C). Therefore, the inhibitory
effect of IFITM3 on HIV-1 cell-to-cell transmission is associated
with a significant decrease of fusion between infected and target
cells, suggesting a decrease in virus production from infected
cells and/or a defect in the fusion capacity of membranes pre-
sent at cell-cell contacts.
IFITM3 Diminishes Virus Infectivity and Incorporates
into Virions
To uncover the mechanisms involved in this restriction, we
studied the impact of expressing IFITM3 in productively infected
cells. In SupT1 cells, overnight induction of IFITM3 following
infection resulted in moderately decreased levels of intracellular
Gag and surface Env proteins, asmeasured by themean fluores-
cence intensity of these two proteins in a fraction of infected cells
(Figure 3A). This slight decrease may be the result of IFITM3 pre-
venting viral spread to new targets or of a direct effect of IFITM3
on the production or stability of these viral proteins. Accordingly,
the amount of Gag antigen detected in the supernatants was
decreased (Figure 3B).
Notably, virus recovery from the supernatants, followed by
sucrose purification, normalization to p24 antigen, and infection
of fresh SupT1 target cells, revealed that IFITM3 proteins
strongly reduced virion infectivity; virus produced from IFITM3-
expressing infected cells was 4–5 times less infectious
(Figure 3C). The decrease in infectivity was 2-fold when virions
were tested onHeLa-CD4 reporter cells (Figure S3A). HIV-1 likely
utilizes different entry pathways when infecting T cells or HeLa-
CD4 cells, and this may affect virus sensitivity to restriction by
IFITM3.
To further describe the effect of IFITM3 on infectivity, we
analyzed virion content. When IFITM3 was present in the virus-
producing cell, it was detected in released virus particles,
purified by a double ultracentrifugation through sucrose and
Optiprep cushions (Figure 3D). IFITM3 also cosedimented with
Gag proteins when viral particles were highly purified on a 6%–
18% Optiprep velocity gradient to discriminate between virus
particles and microvesicles (Figure S3B). Notably, IFITM3 did
not affect the levels of viral envelope glycoproteins incorporated
into virions (Figure 3D). Detergent treatment, to strip away the
viral membrane (Accola et al., 2000), removed the membrane-
associated p17 Gag (MA), as well as IFITM3, while viral core pro-
tein p24 Gag (CA) remained (Figure 3D). This strongly suggests
an association of IFITM3 with the viral membrane rather than
with the core.
We then performed a dose-response analysis of the antiviral
effect of IFITM3. By incrementally increasing IFITM3 protein
levels in 293T cells, we observed increasing amounts of IFITM3
incorporated into virions, correlating with a decrease in particle
infectivity (Figure 3E). Levels of Gag in 293T cells, as well as
Gag released in supernatants, wereminimally affected by IFITM3
expression (Figure S3C). To provide further evidence of IFITM3
incorporation into virus particles, virus prepared in the presence
or absence of IFITM3-FLAG was immunolabeled with anti-FLAG
and protein A-gold. Immunogold labeling revealed specific
detection of IFITM3 at or close to the virion surface (Figures 3F
and S4A).evier Inc.
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Figure 2. Real-Time Video Microscopy Analysis of HIV-1 Spread and Syncytia Formation
(A) SupT1 cells were infected by HIV-IRES-GFP/VSV or HIVDEnv-IRES-GFP/VSV for 2 days. FLAG-IFITM3 was then induced or not induced in infected cells.
These cells were adjusted for Gag+ levels and mixed with target SupT1-actin-mRFP cells, expressing or not expressing IFITM3. Images were taken every 5 min
for 60 hr. The area of GFP and RFP colocalized pixels was quantified and used as amarker of target cell infection. Six fields in two independent experiments were
analyzed and plotted as mean ± SEM. See Movie S1 for a representative time-lapse and Figure S2 for flow cytometry analysis of the experiment.
(B) Clearly identifiable, oversized infected cells were considered as syncytia and visually scored at the indicated time points. Six fields in two experiments were
analyzed and plotted as mean ± SEM.
(C) Images extracted fromMovie S1were extracted at the indicated time points and centered on a cell cluster. White arrows indicate examples of syncytia. Mann-
Whitney test, *p < 0.05. See also Movie S1 and Figure S2.
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IFITM Proteins in HIV Membranes Restrict FusionEndogenous IFITM Proteins Restrict HIV-1 Cell-to-Cell
Transmission
Our experiments show that the ectopic expression of IFITM3 in
virus-producing SupT1 lymphocytes and 293T cells restricts viral
spread. We used HeLa cells to address whether endogenous
IFITM proteins also exhibit this antiviral potential. Flow cytometry
analysis with two antibodies recognizing IFITM1 and IFITM2/
IFITM3, respectively, indicated that HeLa cells naturally express
IFITM2/3 and very little of IFITM1 (Lu et al., 2011). The expression
of all three proteins was upregulated by type I IFN (Figure 4A).
Furthermore, endogenous IFITM2/3 is incorporated into virions
produced from HeLa cells, but not from 293T cells, which ex-
press only trace amounts of IFITM proteins (Figures S4B and
S4C). We thus silenced the three ifitm genes by siRNA in type I
IFN-treated cells (Figure 4A). These cells were infected with
VSV-G pseudotyped HIV-1, and their ability to transmit infectionCell Host &was assessed by performing a coculture with SupT1 target cells.
Knockdown of endogenous IFITM proteins resulted in a 2- to 3-
fold increase in virus transmission to targets (Figure 4B) and the
production of virions that were 3-foldmore infectious (Figure 4C).
Thus, endogenous IFITM proteins in infected cells limit viral cell-
to-cell spread and reduce virion infectivity.
IFITM in Virus-Producing Cells Prevents Fusion
between Virus and Target Cells
We next explored the mechanism by which IFITM3 in donor cells
may diminish virion infectivity. As IFITM residing in endosomal
membranes block the entry of many viruses at the stage of
fusion, we predicted that IFITM localized to the viral membrane
would have similar effects. To quantify HIV-1 entry, we used
a virion fusion assay, which allows the discrimination between
viral entry into the cytoplasm and endosomal captureMicrobe 16, 736–747, December 10, 2014 ª2014 Elsevier Inc. 739
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Figure 3. IFITM3 in Infected Cells Diminishes
Virus Infectivity and Incorporates into Virions
(A) SupT1 cells were infected with HIV-1 for 48 hr and
induced or not induced to express FLAG-IFITM3.
Levels of HIV-1 Env at the surface and of intracellular
Gag were measured by flow cytometry, with the
percentage of Gag+Env+ cells notated. One repre-
sentative experiment is shown.
(B) Left: the mean fluorescence intensity (MFI) of Gag
was measured in the fraction of Gag+ cells. Right:
Gag p24 antigen levels in the supernatantsmeasured
by ELISA. Gag MFI and p24 levels in the absence of
IFITM3 were normalized to 100%. Mean ± SD of five
independent experiments is shown.
(C) Viral supernatants from IFITM3 positive and
negative SupT1 cells were tested for infectivity.
Viral particles were purified, and the inoculum
(adjusted for 25 ng p24) was added to fresh SupT1
cells. Infection was assessed by measuring the
fraction of Gag+ cells after 2 days. Infection in the
absence of IFITM3 was normalized to 100%. Mean ±
SD of four independent experiments is shown
(see also Figure S3A for infectivity assay on HeLa-
CD4 cells).
(D) Viral particles from FLAG-IFITM3 positive and
negative SupT1 cells were purified by a double
ultracentrifugation on cushions of sucrose and Op-
tiprep and analyzed by western blot. One represen-
tative experiment is shown, with 25 ng of p24 loaded
in each lane and probed with anti-FLAG.
(E) 293T cells were cotransfected with a pNL4-3
provirus and with increasing doses of FLAG-IFITM3
expression plasmid. Viral particles released in
supernatants were harvested, and infectivity was
assessed on HeLa-CD4 cells, with 100% corre-
sponding to virions produced without IFITM3.
Mean ± SD of three independent experiments is
shown. MxA expression plasmid was used as a
control. Levels of IFITM3 in 293T cell lysates and
purified virions are shown in the lower panels.
(F) Purified virus particles, produced in 293T cells
cotransfected with pNL4-3 and either IFITM3-FLAG
or control plasmid, were fixed and immunogold
labeled with anti-FLAG. Representative fields are
shown. Other fields are shown in Figure S4A. Scale
bar, 100 nm. A Wilcoxon signed-rank test was per-
formed on raw values in (B) and (C), and a one-
sample t test was performed in (E); *p < 0.05. See
also Figures S3 and S4.
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IFITM Proteins in HIV Membranes Restrict Fusion(Cavrois et al., 2002; Roesch et al., 2012). This assay relies on the
use of viruses containing a b-lactamase-Vpr (blam-Vpr) protein
chimera. The cytoplasmic access of blam-Vpr as a result of
fusion, after 2 hr of infection, is monitored by the enzymatic
cleavage of CCF2-AM, a fluorogenic substrate of b-lactamase
loaded in target cells. A typical experiment showed that virions
produced in the presence of IFITM3 exhibited a marked defect
for fusion with recipient SupT1 lymphocytes (Figure 5A). As a
negative control, HIV encoding fusion-defective Env (HIV-1740 Cell Host & Microbe 16, 736–747, December 10, 2014 ª2014 Elsevier Inc.F522Y) did not enter the cytoplasm (Fig-
ure 5A). Virions incorporating IFITM3
decreased the fusogenicity of virions by
5- to 10-fold (Figure 5B) using eitherSupT1 or MT4C5 T cell lines as targets. Analysis of Gag expres-
sion at a later time point (48 hr postinfection [p.i.]) confirmed that
productive infection was strongly impaired in both target
cells (Figure 5C). We then used viral particles produced in the
presence of IFITM1, IFITM2, or IFITM3. The three proteins
were individually incorporated into particles (Figure S5A), and
all decreased viral fusion to different extents (Figure S5B).
IFITM3 was the most potent, while IFITM1 and IFITM2 imposed
a restriction of approximately 2-fold. An untagged version of
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Figure 4. Endogenous IFITM Proteins in In-
fected Cells Inhibit the Spread of HIV-1
(A) HeLa cells were transfected with control siRNA
(si Con) or with siRNA targeting the three IFITM (si
IFITM) and treated with IFNa2a for 48 hr. IFITM1
and IFITM2/3 levels were assessed by flow
cytometry. A representative experiment is shown.
(B and C) These cells were simultaneously infected
with NL4-3 (VSV). Viral supernatants were har-
vested 48 hr later, and cells served as donors in a
transmission assay. (B) HeLa cells were coculti-
vated with SupT1 targets for 2 hr, target cells were
harvested, and transmission wasmonitored at day
2 p.i. Mean ± SD of three independent experi-
ments. (C) Viral supernatants from silenced cells
were measured for infectivity as described in Fig-
ure 3. Infection by virions produced in the si Con
cells was normalized to 100%. Mean ± SD of three
independent experiments is shown. Mann-Whit-
ney test, *p < 0.05. See also Figure S4.
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IFITM Proteins in HIV Membranes Restrict FusionIFITM3 displayed a similar capacity to block virion fusion
(Figure S5C).
We then analyzed fusion after cell-to-cell viral transfer. After
2 hr of coculture with blam-Vpr-positive infected 293T donor
cells, expressing or not expressing IFITM, we harvested SupT1
target cells and analyzed CCF2-AM cleavage. The three IFITM
proteins, when present in donor cells, also inhibited viral fusion
in this setting (Figure S5D).
It has been reported that cellular membrane-resident IFITM2
and IFITM3 in target cells partially decrease HIV-1 entry (Lu
et al., 2011). Therefore, we tested how virion-incorporated
IFITM3 compares with cellular IFITM3 with regards to blocking
virus fusion by performing the fusion assay using SupT1 target
cells expressing or not expressing IFITM3 (Figure 5D). An effect
of IFITM3 in target cells was observed only when low doses of
virus were used, confirming that restriction in the recipient
lymphocyte is modest (Figure 5D). In contrast, the fusion of virus
containing IFITM3 was strongly restricted, regardless of the viral
inoculum used (Figure 5D). This effect was even greater when
both virions and cellular membranes were expressing IFITM3.
Thus, the effect of IFITM3 in target cells is saturable and exerts
a relatively weak block to virus entry compared to the activity
of virion-incorporated IFITM3. These results strongly suggest
that IFITM proteins are dramatically more effective at restricting
virus-cell fusion when localized to the viral membrane.
Endogenous IFITM Proteins Are Upregulated in
Activated CD4+ T Cells and Incorporate into HIV-1
Virions during Infection
As the principal targets of HIV-1 infection in vivo, we measured
the levels of endogenous IFITM proteins in primary CD4+
T cells and addressed how they are affected by cell activation
status and type I IFN treatment. Nonactivated CD4+ T cells con-Cell Host & Microbe 16, 736–747, Dtained low, but detectable, levels of
IFITM1 and IFITM2/3, with the former ex-
pressed to a higher extent (Figure 6A).
Upon activation by phytohemagluttinin
(PHA) and interleukin-2 (IL-2), IFITM levelswere increased, consistent with a previous report showing IFITM
induction upon T cell activation (Raposo et al., 2013). Addition of
type I IFN further upregulated these proteins, with IFITM1
showing a greater degree of induction (Figure 6A). Staining
without saponin permeabilization indicated that a fraction of
IFITM proteins was present at the cell surface, with levels
increasing upon type I IFN treatment (Figure S6B). The levels
of IFITM proteins in type I IFN-treated CD4+ T cells were within
the range of those observed in doxycycline-induced SupT1
T cells (data not shown).
We used confocal immunofluorescence microscopy to track
the localization of IFITM2/3 in uninfected and infected primary
CD4+ T cells. IFITM2/3 expression in the uninfected cell
appeared primarily as small puncta distributed throughout the
cytoplasmandpartially colocalizedwith endosomal or lysosomal
markers (transferrin receptor, CD63, and LAMP1/LAMP2),
consistent with previous reports using nonlymphoid human cell
lines (Amini-Bavil-Olyaee et al., 2013; Feeley et al., 2011;Weston
et al., 2014) (Figure 6B and data not shown). Upon infection, the
signal for IFITM2/3 protein appeared elevated and often shifted
to a mostly perinuclear localization (Figure 6C). Interestingly,
IFITM2/3 staining often colocalized with that of HIV-1 Env in
the cell interior, while surface-associated IFITM2/3 could also
be observed at probable virus budding sites containing both
Env andGag (Figure 6C). IFITM3was also detected within virions
produced from SupT1 cells expressing an Env-deleted HIV-1,
indicating that IFITM3 can be incorporated through an Env-inde-
pendent mechanism (Figure S6A). Costaining of IFITM1 and
IFITM2/3 showed that the proteins display overlap in their distri-
bution within HIV-1-infected cells and that IFITM proteins coloc-
alize with viral Gag protein on the cell surface (Figure S6C).
By infecting primary, activated CD4+ T cells with primary
HIV-1 isolates (DH12, Bx08, and BON strains), or the NL4-3ecember 10, 2014 ª2014 Elsevier Inc. 741
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(A) One representative test for viral fusion. SupT1
cells were exposed to virions containing Blam-Vpr,
produced in the presence or absence of FLAG-
IFITM3, for 2 hr at 37C. Viral access to the cyto-
plasm was assessed by flow cytometry, using the
cleavage of CCF2-AM as a readout. F552Y: non-
fusogenic env mutant.
(B) Fusion of virions produced in the absence of
IFITM3 was normalized to 100%. Two different
target cells were used, SupT1 and MT4C5 cells.
Mean ± SD of three independent experiments.
(C)Virionsused for the fusionassaywerealso tested
for their infectivity. Viral inoculum (adjusted for 25ng
p24)wasaddedon freshSupT1orMT4C5cells, and
infection was assessed by Gag+ cells after 2 days.
Infection by virions produced in the absence of
IFITM3 was normalized to 100%. Mean ± SD of
three independent experiments is shown.
(D) Virions produced as described in (A) were tested
for fusion on target SupT1 cells expressing or not
expressing IFITM3. A titration of the viral inoculum
was performed, with the maximum dose corre-
sponding to 25 ng Gag p24. Mean ± SD of three
independent experiments is shown. Mann-Whitney
test, *p < 0.05. Comparisons were made between
thecondition indicatedand theNo IFITM3condition.
See also Figure S5.
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naturally incorporated into virions. Endogenous IFITM proteins
were detected in purified viral particles (Figure 6D), with the
extent of incorporation slightly varying between viral isolates.
Therefore, IFITM proteins present in primary CD4+ T cells are
capable of infiltrating virus particles. Notably, immature mono-
cyte-derived dendritic cells (MDDCs) also expressed IFITM pro-
teins, which were upregulated upon cellular maturation or by
type I IFN (Figure S6D).
Altogether, our results show that endogenous IFITM proteins
are found in primary T cells and MDDCs. In T cells, they colocal-
ize with viral proteins and are incorporated into viral particles.
Therefore, the antiviral functions of IFITM proteins described
herein may be relevant for natural HIV-1 infections.
DISCUSSION
IFITM proteins belong to the CD225 protein superfamily, which
can be found in nearly every domain of life, ranging from bacteria
to invertebrates to primates. The array of ifitm genes in humans
and other species most likely originated via tandem gene dupli-
cation events in our early vertebrate ancestors (Hickford et al.,
2012; Siegrist et al., 2011). The expansion of ifitm loci suggests
that the antiviral properties of IFITM, and possibly those of
other CD225 proteins, have been selected and retained for pro-
tection against viral infections. Here, we describe a function of742 Cell Host & Microbe 16, 736–747, December 10, 2014 ª2014 Elsevier Inc.IFITM that may be important for its con-
servation over evolutionary time.
We show that HIV-1 cell-to-cell trans-
mission allows the virus to bypass IFITM
restriction in target cells. However, IFITMproteins limit the spread of virus from infected cells, at least in
part by rendering virions less infectious and less fusogenic. Inter-
estingly, while IFITM3 in uninfected lymphocytes has a minimal
protective effect against HIV-1, it serves an additive antiviral
role when IFITM3 is also present within incoming virions. The
reason for this may lie with the accepted mechanism by which
IFITM proteins inhibit the fusion capacity of membranes in which
they reside. IFITM proteins inhibit steps leading to the formation
of a fusion pore by increasing the curvature of cell membranes
and reducing their fluidity (Desai et al., 2014; Li et al., 2013; Lin
et al., 2013). If IFITM3 similarly contorts the viral membrane
and causes similar biophysical consequences (Everitt et al.,
2012) then the apposition of two IFITM3-containing membranes
may make virus-cell fusion even more unlikely. Alternatively,
IFITM incorporation into viral membranes may indirectly affect
fusogenicity by excluding factors necessary for virus-cell fusion
or by recruiting other inhibitors of this process. For example,
while we did not detect differences in Env glycoprotein levels
in virions containing or not containing IFITM3, Env conformation
may be compromised. Although unlikely, this hypothesis
deserves further investigation.
Despite that IFITM proteins may be localized to different
cellular compartments in the absence of infection, with IFITM1
residing primarily at the plasma membrane (John et al., 2013;
Mudhasani et al., 2013) and IFITM2 and IFITM3 residing in late
endosomes and lysosomes (Amini-Bavil-Olyaee et al., 2013;
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IFITM Proteins in HIV Membranes Restrict FusionFeeley et al., 2011; Weston et al., 2014), we detect all of them in
HIV-1 virions. This could be explained by the fact that all IFITM
proteins transit, at least transiently, to the cell surface following
translation (Chesarino et al., 2014; Jia et al., 2014; Weston
et al., 2014). HIV-1 virion assembly is thought to occur primarily
at the plasma membrane but may also occur in an intracellular
compartment connected to the surface in some cell types,
such as macrophages (Deneka et al., 2007; Jouve et al., 2007;
Sundquist and Kra¨usslich, 2012; Welsch et al., 2007). Our
confocal microscopy analysis of primary infected lymphocytes
demonstrated a colocalization of IFITM proteins with viral pro-
teins Env and (to a lesser extent) Gag. Targeting to lipid rafts,
which have been shown to harbor IFITM1 (Perreira et al.,
2013), is important for optimal virus release (Tang et al., 2009).
Therefore, there are numerous potential meeting sites for the
virus and IFITM within infected cells. Our time-lapse analysis of
cell-to-cell transmission demonstrated a striking diminution of
syncytia formation between IFITM3-expressing cells. Syncytia
are likely the consequence of fusion events occurring at the
plasma membrane. This further suggests that the surface of
the productively infected cell is the main site at which IFITM3
exerts this antiviral function. We also observed an increase in
cell surface-associated IFITM2/3 following IFN treatment. This
complements published data indicating that IFN treatment or
overexpression modifies IFITM localization (Brass et al., 2009;
Perreira et al., 2013). Further work will aid in our understanding
of how HIV-1 impacts IFITM localization. Interestingly, we
showed here that Env is not required for IFITM3 incorporation
into virions. Addressing the passive or active nature of IFITM
association with virions will require the identification of virus
strains or mutants that exhibit differential sensitivity to IFITM
virion infiltration. Such differences, if they should exist, may lie
in different strategies used by viruses to assemble and egress
from the infected cell.
In uninfected cells, the protective effect of IFITM is dependent
on their intracellular localization. The trafficking and localization
of IFITM is regulated by sortingmotifs within the N-terminal intra-
cytoplasmic domain and by palmitoylated cysteine residues
(Ding et al., 2014; Yount et al., 2010). IFITM function is also regu-
lated by phosphorylation (Chesarino et al., 2014). It will be worth-
while to use various IFITMmutants to determine precisely where
and how these proteins are incorporated into viral particles. We
show here that IFITM proteins are expressed and upregulated by
type I IFN in primary T lymphocytes and in DCs, two natural tar-
gets of HIV-1 in vivo. In these cells, as well as in macrophages,
viral entry, budding, and egress pathways display notable differ-
ences. Further work will address the cell-type specificity of this
restriction activity of IFITM.
Apart from our finding that IFITM proteins become incorpo-
rated into virus particles and decrease particle infectivity, we
also observed that ectopic IFITM expression slightly decreases
viral production. The presence of IFITM3 in infected SupT1
T cells or in transfected 293T cells resulted in modest decreases
in HIV-1 Gag expression, consistent with articles reporting
similar findings in these two cell types (Chutiwitoonchai et al.,
2013; Ding et al., 2014; Lu et al., 2011). However, by introducing
limiting amounts of IFITM3 in 293T, we observed an inhibition of
virus transmission without affecting viral production. Therefore,
we believe that the block in virus transmission conferred byCell Host &IFITM3 is primarily the result of decreased viral infectivity and
fusogenicity. It will also be worth determining whether IFITM
proteins accumulate at or modify the formation of virological
synapses between infected and uninfected T cells.
Now that we have expanded our understanding of how IFITM
proteins contribute to intrinsic immunity, it will be important
to study these functions in the context of other enveloped
viruses. This analysis may reveal whether viruses sensitive to
IFITM in the target cell are also susceptible to this donor cell-
specific mode of antiviral function, i.e., virion incorporation
and decreased infectivity. Furthermore, it will be important to
addresswhether viruses previously described as IFITM-resistant
(murine leukemia virus, arenaviruses) are in fact sensitive to this
mode of inhibition. Furthermore, future experiments will require
attention to the virus-producing cell type, especially the combi-
nation of donor and target cells used in experiments. Since IFITM
proteins are known to form homo- and heteromultimers, and
these interactions are necessary for full antiviral activity (John
et al., 2013), combinatorial approaches must be employed to
study their collective activity, in both the cell and the virion.
Together, these approaches will reveal the full breadth and po-
tency of IFITM proteins.
A recent report highlighted that HIV-1 can evolve resistance to
IFITM1 in vitro through mutations in Env and Vpu proteins, with
an effect of increasing viral fitness via enhancement of cell-to-
cell spread (Ding et al., 2014). This concurs with our results
showing that HIV-1 cell-to-cell transmission is less sensitive to
IFITM-mediated restriction than cell-free virus infection. Viral
cell-to-cell transmission may also help explain why Brass et al.
(2009) did not observe a potent antiviral effect of IFITM3 in
HeLa-derived cells. Another nonspecific strategy to evade
IFITM3 restriction has been described for IAV (Wang et al.,
2014), but no direct anti-IFITM3 activity has thus far been identi-
fied for any virus. A growing list of viruses has evolved mecha-
nisms to antagonize or degrade various cellular proteins, which
offers additional support in favor of their classification as restric-
tion factors (Duggal and Emerman, 2012). The use of HIV-1
mutants carrying mutations in viral accessory or structural
genes, as well as IFITM variants containing synthetic or naturally
occurring polymorphisms, will reveal potential interactions
between HIV-1 and IFITM proteins and their consequences
on infection. Furthermore, extending the functional characteriza-
tion of IFITM proteins beyond humans will allow us to assess
whether sequence divergence across taxa may play a role in
cross-species virus transmission events.
EXPERIMENTAL PROCEDURES
Cells, Viruses, and Reagents
Primary CD4+ T lymphocytes, MDDCs, and SupT1 and MT4C5 T cell lines
were generated and grown as described (Lepelley et al., 2011). pQCXIP plas-
mids encoding IFITM1, IFITM2, and IFITM3 with N-ter FLAG (FLAG-IFITM) or
C-ter FLAG (IFITM-FLAG) were described (Lu et al., 2011). Tet-ifitm SupT1
cells were treated with doxycycline (500 ng/ml) overnight to induce FLAG-
IFITM as described (Lu et al., 2011). Nevirapine (25 mM) was from the NIH
AIDS reagents program. When stated, cells were treated with 500 IU/ml of
IFN-a2a (PBL Biomedical Laboratories) and analyzed 48 hr later. The HIV-1
NL4-3 strain, the primary strains DH12, Bx08, and BON, and NL4-3-IRES-
GFP have been described (Sourisseau et al., 2007; Lepelley et al., 2011;
Wildum et al., 2006). Virus stocks were produced as described (Lepelley
et al., 2011).Microbe 16, 736–747, December 10, 2014 ª2014 Elsevier Inc. 743
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Figure 6. Expression, Localization, and Virion Incorporation of IFITM in Primary T Cells
(A) Nonactivated and PHA-activated CD4+ T cells treated or not treated with IFNa2a for 48 hr were analyzed by flow cytometry to measure IFITM1 and IFITM2/3
levels. One representative experiment among five donors is shown.
(B) Noninfected activated CD4+ T cells were stained with anti-IFITM2/3 (in red). Blue, DAPI (nuclei). Representative fields with cells from three donors
are shown.
(legend continued on next page)
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SupT1 or primary CD4+ T cells were infected with cell-free virus as described
(Lepelley et al., 2011). For the virus cell-to-cell transmission assay utilizing
SupT1 as donors, 5 3 106 cells were first infected with 100–200 ng NL4-3
and cultured for 2 days to achieve 30%–50% Gag+ cells. Cells were then
induced or not induced for IFITM. A total of 1 3 105 donor cells was mixed
with 3 3 105 target SupT1 cells labeled with CellTrace Far Red DDAO-SE
(Life Technologies) in 24-well plates. After 2 hr, 23 105 target (Far Red+) cells
were collected and separated from donors using a FACSAria cell sorter and
plated in a 96-well plate. Cells were then analyzed by flow cytometry. When
293T cell were used as donors, 1 3 105 cells were cotransfected in a
24-well plate with the pNL4-3 provirus (1 mg) and FLAG-IFITM (1 mg, unless
otherwise stated) using Metafectene transfection reagent (Biontex). A total
of 3 3 105 labeled SupT1 targets (1:3 donor:target) were added 48 hr later.
After 2 hr of coculture, targets were manually separated from donors and
transferred to a 48-well plate. To measure infectivity, viral particles were puri-
fied on a sucrose cushion, and the inoculum (adjusted for p24 content) was
added to fresh SupT1 cells. Unless otherwise stated, 25 ng of p24 was added
to 105 cells. Infection was assessed by measuring the fraction of Gag+ cells
after 2–3 days.
Flow Cytometry
The following antibodies were used: IFITM1 (Proteintech, 60074-1-Ig), IFITM2
(Proteintech, 12769-1-AP), IFITM3 (Proteintech, 11714-1-AP), Env (4546,
kindly provided by HugoMouquet; Malbec et al., 2013), and Gag (KC57, Beck-
man Coulter). We noticed that rabbit anti-IFITM3 partially cross-reacted with
IFITM2, as observed using Tet-ifitm2 SupT1 cells. Endogenous protein recog-
nized with anti-IFITM3 is thus referred to as IFITM2/3. Anti-Env antibodies
were added before fixation. For stainings, cells were fixed with 4% PFA and,
when stated, permeabilized with 0.5% saponin. Isotype-matched antibodies
were used as negative controls. Samples were analyzed with a FACS Canto
II (Becton Dickinson).
Time-Lapse Video Imaging
Cells were plated on Hi-Q4 microdishes (Ibidi) precoated with 10 mg/ml fibro-
nectin (Sigma). Tet-ifitm3 SupT1 cells transduced to express actin-mRFP
were used as targets. A total of 7 3 105 donor cells infected with HIV-1-
IRES-GFP (Wildum et al., 2006) (about 15% of Gag+ cells) was mixed with
73 105 cells. Transmission and fluorescence images were taken at 37C every
5 min up to 60 hr using a Nikon Biostation IMQ, with three fields for each con-
dition. After 60 hr, cells were analyzed by flow cytometry. Images were
analyzed using FIJI software. Threshold levels in GFP and RFP were added
and used to calculate dual-positive pixels and to determine the area of double
GFP/RFP regions per field. Syncytia were visually scored based on their
morphology and GFP expression.
Western Blot
Cells were lysed in 1% Triton/PBS in the presence of a protease inhibitor
cocktail. Purified virions released from transfected 293T cells and infected
SupT1 or primary CD4+ lymphocytes were used to assess protein incorpora-
tion. The virus-containing supernatant was overlaid on a 20% sucrose
cushion, and particles were pelleted by centrifugation (50,000 3 g, 4C) for
90 min. Viral pellets were reoverlaid on a 6% Optiprep cushion and resus-
pended in lysis buffer. An aliquot was removed for p24 Gag quantification by
ELISA, and normalized amounts were loaded for SDS-PAGE. The following
antibodies were used: IFITM (see above), FLAG M2 (Sigma), Gag p24 (183-
H12-5C), and Env (110H, Institut Pasteur). The purification of HIV-1 particles
by velocity gradients was performed as described in the Supplemental Exper-
imental Procedures.(C) PHA-activated CD4+ T cells were infected with NL4-3 for 3 days and staine
recognizing p17 and not theGag p55 precursor) (white) monoclonal antibodies (mA
Scale bar, 5 mm.
(D) PHA-activated CD4+ T cells were infected with DH12, Bx08, and BON primar
released were purified and analyzed by western blot with the indicated antibodies
lane. For NL4-3, an additional dose of 2 ng is shown. See also Figure S6.
Cell Host &b-Lactamase-Vpr Assay
Viral fusion was assessed as described (Casartelli et al., 2010; Cavrois et al.,
2002). Briefly, virions containing the blam-Vpr fusion protein were produced
by cotransfecting 293T cells with a 3:1.5:1 ratio of pNL4-3, FLAG-IFITM3,
andblam-Vpr plasmids, respectively. A total of 25ngGagp24ofblam-Vpr-con-
taining virions was exposed to 13 105 SupT1 or MT4C5. After 2 hr, cells were
incubated with the CCF2-AM substrate (CCF2-AM kit, Invitrogen) for 2 hr. The
cleavedCCF2-AM fluorescencewas thenmeasured by flow cytometry. The vi-
rus-target cell fusion assaywasperformed asdescribed (Casartelli et al., 2010).
siRNA Knockdown of IFITM Proteins in HeLa Cells
siRNA (Silencer Select, Ambion) targeted IFITM1 (s16192), IFITM2 (s20771),
and IFITM3 (s195035). Silencing in HeLa was performed as described (Lu
et al., 2011). A mixture containing 10 nM of each siRNA was used to deplete
the three IFITM proteins. Cells were simultaneously exposed to HIV-1(VSV)
pseudotypes (5 ng p24/ml in a 12-well plate) in the presence of 500 IU/ml
IFN-a2a. After 48 hr, viruses were harvested, and cells were used in coculture
assays with SupT1 as targets. IFITM levels were assessed by flow cytometry.
Purification of HIV-1 Particles by Velocity Gradients
Virion purification by Opti-prep fractionation was performed as described
(Arenaccio et al., 2014) (Cantin et al., 2008) with minor modifications (Supple-
mental Experimental Procedures).
Immunogold Labeling of Isolated Viral Particles for Transmission
Electron Microscopy
293T cells were cotransfected with a 2:1 ratio of pNL4-3 and pQCXIP IFITM3-
FLAG or control plasmid, and supernatants were harvested 48 hr later. Trans-
mission electron microscopy was performed as described (Le Gall et al., 1997)
(Shaw et al., 2008), with modifications. Viral particles were concentrated from
supernatants by ultracentrifugation over 20% sucrose cushions. Before depo-
sition of the particle suspension on carbon-coated 200mesh copper palladium
grids, the grids were glow discharged in a Quorum Q150R ES (Quorum). After
adhesion, particles were chemically fixed with 4% paraformaldehyde in 0.1 M
PHEM buffer (pH 7.2). Remaining free aldehydes were quenched with 50 mM
NH4Cl in PBS before labeling with mouse anti-FLAG (M2) antibody (Sigma),
followed by a rabbit anti-mouse immunoglobulin G (IgG) (Dako) and 10 nm
protein A gold (CMC). After labeling, grids were negatively stained with
aqueous 4% uranyl acetate solution and viewed in a Tecnai Spirit electron
microscope operated at 120 kV (FEI).
Confocal Immunofluorescent Microscopy
HIV-1-infected CD4+ T cells were fixed, permeabilized, and stained with anti-
Gag (mouse anti-p17 ARP342, culture supernatant diluted 1:100; Programme
EVA Centre for AIDS Reagents), anti-Env (clone 110H, 50 mg/ml, Institut
Pasteur), anti-IFITM1, and anti-IFITM3. Confocal microscopy analysis was
carried out on a Zeiss LSM700 using a 633 objective as described (Rudnicka
et al., 2009). Representativemedial sections are shown. Imageswere analyzed
using FIJI software and assembled with the Magic Montage ImageJ plugin.
Statistical Analysis
Statistical analysis was performed using Prism, using specific tests as indi-
cated in the figure legends.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one movie and can be found with this article online at http://
dx.doi.org/10.1016/j.chom.2014.11.001.d with anti-IFITM2/3 (red), anti-Env 110H (green), and anti-p17 Gag (ARP342,
bs). Representative fields with cells from three independent donors are shown.
y HIV-1 strains, or with the NL4-3 laboratory-adapted strain, for 3 days. Virions
. One representative experiment is shown, with 1 ng of Gag p24 loaded in each
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